Press Releases Search News Category Company ReleasesCompany StatementsFinancial ReleasesProduct Releases Year None2024202320222021202020192018201720162015201420132012201120102009200820072006 Date Title PDF Version Jul 10, 2019 Alexion to Report Second Quarter 2019 Results On Wednesday, July 24, 2019 Jul 03, 2019 ULTOMIRIS® (ravulizumab) Receives Marketing Authorization from European Commission for Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH) Jun 27, 2019 Alexion Receives FDA Approval of SOLIRIS® (eculizumab) for the Treatment of Adults with Neuromyelitis Optica Spectrum Disorder (NMOSD) who are Anti-Aquaporin-4 (AQP4) Antibody Positive Jun 20, 2019 U.S. FDA Accepts Supplemental Biologics License Application (sBLA) for ULTOMIRIS® (ravulizumab-cwvz) under Priority Review for the Treatment of Atypical Hemolytic Uremic Syndrome (aHUS) Jun 18, 2019 ULTOMIRIS® (ravulizumab) Receives Marketing Authorization from Japan’s Ministry of Health, Labour and Welfare (MHLW) for the Treatment of Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH) Jun 14, 2019 Positive Phase 3 Extension Data for ULTOMIRIS® (ravulizumab) in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Presented at European Hematology Association (EHA) Congress May 13, 2019 Alexion to Present at the UBS Global Healthcare Conference May 13, 2019 Alexion to Present at the RBC Capital Markets Annual Healthcare Conference May 03, 2019 New England Journal of Medicine Publishes Positive Phase 3 PREVENT Data for SOLIRIS® (eculizumab) in Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD) Apr 26, 2019 Alexion Receives Positive CHMP Opinion for ULTOMIRIS® (ravulizumab) in Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH) Pagination First page « first Previous page ‹ previous … Page 7 Page 8 Page 9 Page 10 Current page 11 Page 12 Page 13 Page 14 Page 15 … Next page next › Last page last » Displaying 101 - 110 of 630